#USA #New York #Class Action #Semler Scientific #Pomerantz LLP

Pomerantz Law Firm Alerts Semler Scientific Investors

On September 28, 2025, the Pomerantz Law Firm announced a critical investor alert regarding Semler Scientific, Inc. (NASDAQ: SMLR). The firm is urging individuals who suffered financial losses as a result of their investments in Semler to come forward as a class action lawsuit has been initiated against the company. The essence of this lawsuit revolves around allegations of securities fraud and potential involvement in unlawful business practices by Semler's executives.

Important Deadlines

Investors interested in participating in this class action have until October 28, 2025, to request the court to appoint them as Lead Plaintiff. To join the action, affected investors can reach out to Danielle Peyton via email at [email protected] or call the toll-free number 888-4-POMLAW (Ext. 7980). For better assistance, it is recommended that investors provide their mailing address, contact number, and the total number of Semler shares they acquired.

Background on the Lawsuit

The class action includes concerns stemming from Semler's annual report for the fiscal year ending in 2024. This report raised alarms as the company disclosed potential liability stemming from an inquiry by the U.S. Department of Justice (DOJ) concerning the peripheral artery disease device known as QuantaFlo. Semler revealed it had received a civil investigative demand regarding its reimbursement claims and indicated discussions with the DOJ had not led to a resolution as of February 2025.

Following the announcement of these concerns, the stock price of Semler dropped 9.4%, closing at $38.89 per share on March 3, 2025, following the report's release. Investors saw further declines when Semler revealed it had reached an agreement in principle with the DOJ for a settlement amounting to $29.75 million for all claims, causing the company's stock price to fall by an additional 9.88% the next day.

Pomerantz Law Firm's Credentials

Pomerantz LLP is widely recognized for its expertise in corporate, securities, and antitrust class litigation. Founded over 85 years ago by Abraham L. Pomerantz, the firm has continuously fought for the rights of investors impacted by fraudulent activities and breaches of fiduciary duty. The firm claims to have secured substantial settlements and damages for its clients, demonstrating a long-standing commitment to justice in financial sectors.

With offices located in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz LLP remains at the forefront of activism against corporate malfeasance. It is crucial for investors to understand that by engaging in this class action, they join a collective effort that could potentially lead to recovery of losses incurred due to the alleged wrongdoings of Semler.

For more information about joining the class action, investors can visit Pomerantz Law Firm's website where a copy of the filed complaint is available.

Conclusion

The unfolding situation surrounding Semler Scientific, Inc. emphasizes the need for vigilance among investors. As the legal landscape shaped by class actions evolves, affected investors must act swiftly to protect their interests. This lawsuit represents both a challenge for Semler and an opportunity for investors to seek recourse against potential fraud.

For legal inquiries or specific concerns, Pomerantz LLP's specialists remain available to assist investors throughout this turbulent period. Prompt action is essential, as the deadline for filing as Lead Plaintiff approaches.